Literature DB >> 9666938

Biochemical markers of bone formation in the study of postmenopausal osteoporosis.

C Dominguez Cabrera1, M Sosa Henríquez, M L Traba, E Alvarez Villafañe, C de la Piedra.   

Abstract

A comparative study was performed on the sensitivity of the determination of the available biochemical markers of bone formation--total and bone alkaline phosphatase (TAP and bAP, respectively), osteocalcin (BGP), procollagen I aminoterminal propeptide (PINP) and procollagen I carboxyterminal propeptide (PICP)--in the study of postmenopausal osteoporosis. The comparison between PINP and PICP, due to the recent development of the amino-terminal assay, is of special interest. The study included 26 untreated osteoporotic postmenopausal women, age 59 +/- 6 years (range 46-69 years) and 17 healty control postmenopausal women, age 56 +/- 7 years (range 48-70 years). We found a significant increase in the levels of bAP (p = 0.0021), BGP (p = 0.041), PINP (p = 0.0001) and PCIP (p = 0.0073), but not in the levels of TAP (p = 0.3389), in osteoporotic patients with respect to the control group. Serum PINP and bAP showed the highest diagnostic accuracy among the markers of bone formation studies, as can be deduced from the receiver operating characteristics (ROC) curves. In spite of their similar origin (amino-terminal and carboxy-terminal release from a procollagen molecule), the results obtained by measuring levels of PINP are significantly better than those found with PICP.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9666938     DOI: 10.1007/bf02672511

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  17 in total

Review 1.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine.

Authors:  M H Zweig; G Campbell
Journal:  Clin Chem       Date:  1993-04       Impact factor: 8.327

2.  Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease.

Authors:  P Garnero; P D Delmas
Journal:  J Clin Endocrinol Metab       Date:  1993-10       Impact factor: 5.958

3.  Synthetic peptide-based immunoassay for amino-terminal propeptide of type I procollagen: application for evaluation of bone formation.

Authors:  S G Linkhart; T A Linkhart; A K Taylor; J E Wergedal; P Bettica; D J Baylink
Journal:  Clin Chem       Date:  1993-11       Impact factor: 8.327

Review 4.  Biochemical markers of bone turnover.

Authors:  P D Delmas
Journal:  J Bone Miner Res       Date:  1993-12       Impact factor: 6.741

5.  Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases.

Authors:  P R Ebeling; J M Peterson; B L Riggs
Journal:  J Bone Miner Res       Date:  1992-11       Impact factor: 6.741

6.  Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro.

Authors:  P Garnero; M Grimaux; P Seguin; P D Delmas
Journal:  J Bone Miner Res       Date:  1994-02       Impact factor: 6.741

7.  Bone Gla protein (osteocalcin) assay standardization report.

Authors:  P D Delmas; C Christiansen; K G Mann; P A Price
Journal:  J Bone Miner Res       Date:  1990-01       Impact factor: 6.741

8.  Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase.

Authors:  A M Parfitt; L S Simon; A R Villanueva; S M Krane
Journal:  J Bone Miner Res       Date:  1987-10       Impact factor: 6.741

9.  Six osteocalcin assays compared.

Authors:  E M Díaz Diego; R Guerrero; C de la Piedra
Journal:  Clin Chem       Date:  1994-11       Impact factor: 8.327

10.  Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen.

Authors:  J Melkko; S Niemi; L Risteli; J Risteli
Journal:  Clin Chem       Date:  1990-07       Impact factor: 8.327

View more
  6 in total

1.  Lycopene consumption decreases oxidative stress and bone resorption markers in postmenopausal women.

Authors:  L G Rao; E S Mackinnon; R G Josse; T M Murray; A Strauss; A V Rao
Journal:  Osteoporos Int       Date:  2006-08-29       Impact factor: 4.507

2.  BMD and Serum Intact Osteocalcin in Postmenopausal Osteoporosis Women.

Authors:  Vanita R Jagtap; Jayashri V Ganu; Nitin S Nagane
Journal:  Indian J Clin Biochem       Date:  2010-09-14

3.  Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.

Authors:  Riitta Tähtelä; J Seppänen; K Laitinen; A Katajamäki; J Risteli; M J Välimäki
Journal:  Osteoporos Int       Date:  2004-12-17       Impact factor: 4.507

4.  Lactation and bone turnover: a conundrum of marked bone loss in the setting of coupled bone turnover.

Authors:  Raquel M Carneiro; Linda Prebehalla; Mary Beth Tedesco; Susan M Sereika; Maryann Hugo; Bruce W Hollis; Caren M Gundberg; Andrew F Stewart; Mara J Horwitz
Journal:  J Clin Endocrinol Metab       Date:  2010-02-11       Impact factor: 5.958

5.  A meta-analysis of serum osteocalcin level in postmenopausal osteoporotic women compared to controls.

Authors:  Zhongyu Liu; Ruiqiang Chen; Yutong Jiang; Yang Yang; Lei He; Chunxiao Luo; Jianwen Dong; Limin Rong
Journal:  BMC Musculoskelet Disord       Date:  2019-11-13       Impact factor: 2.362

6.  Acute response of biochemical bone turnover markers and the associated ground reaction forces to high-impact exercise in postmenopausal women.

Authors:  Rizky S Prawiradilaga; Anders O Madsen; Niklas R Jørgensen; Eva W Helge
Journal:  Biol Sport       Date:  2020-01-24       Impact factor: 2.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.